EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC

Yuanxiang Lu iD, Jinghan Zhu, Yuxin Zhang, Wentao Li, Yixiao Xiong, Yunhui Fan, Yang Wu, Jianping Zhao, Changzhen Shang, Huifang Liang, Wanguang Zhang iD

Advanced Science · 2024-12 · 11 (46)

DOI: 10.1002/advs.202401399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.10.2024. Verfasst von Yuanxiang Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 43…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Quinolines, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance remains a bottleneck for molecular‐targeted therapy in advanced hepatocellular carcinoma (HCC). Metabolic adaptation and epigenetic remodeling are recognized as hallmarks of cancer that may contribute to acquired resistance. In various lenvatinib‐resistant models, increased glycolysis leads to lactate accumulation and lysine lactylation of IGF2BP3. This lactylation is crucial for capturing PCK2 and NRF2 mRNAs, thereby enhancing their expression. This process reprograms serine metabolism and strengthens the antioxidant defense system. Additionally, altered serine metabolism increases the availability of methylated substrates, such as S‐adenosylmethionine (SAM), for N6‐methyladenosine (m6A) methylation of PCK2 and NRF2 mRNAs. The lactylated IGF2BP3‐PCK2‐SAM‐m6A loop maintains elevated PCK2 and NRF2 levels, enhancing the antioxidant system and promoting lenvatinib resistance in HCC. Treatment with liposomes carrying siRNAs targeting IGF2BP3 or the glycolysis inhibitor 2‐DG restored lenvatinib sensitivity in vivo. These findings highlight the connection between metabolic reprogramming and epigenetic regulation and suggest that targeting metabolic pathways may offer new strategies to overcome lenvatinib resistance in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularQuinolinesLiver NeoplasmsDrug Resistance, NeoplasmRNA-Binding ProteinsPhenylurea CompoundsHumansMiceAnimalsSerineAntineoplastic AgentsDisease Models, AnimalCell Line, TumorMetabolic Reprogramming

Stichwörter der Autor:innen

IGF2BP3 lactylationPCK2glycolysislenvatinib resistanceserine metabolism

Substanzen

QuinolineslenvatinibRNA-Binding ProteinsPhenylurea CompoundsIGF2BP3 protein, humanSerineAntineoplastic Agents

Autor:innen und Institutionen

  • Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 430030, China.
  • Department of Breast Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
  • Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei, 430030, China.
  • Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
  • Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, 430030, China.
  • Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Yanjiang West Road, Guangzhou, 510120, China.

ORCID-Profile: Yuanxiang Lu, Wanguang Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lu, Y., Zhu, J., Zhang, Y., Li, W., Xiong, Y., Fan, Y., Wu, Y., Zhao, J., Shang, C., Liang, H., & Zhang, W. (2024). Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC. Advanced Science, 11(46). https://doi.org/10.1002/advs.202401399

Vancouver

Lu Y, Zhu J, Zhang Y, Li W, Xiong Y, Fan Y, et al. Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC. Advanced Science. 2024;11(46). doi:10.1002/advs.202401399

BibTeX
@article{Lu2024,
  author = {Lu, Yuanxiang and Zhu, Jinghan and Zhang, Yuxin and Li, Wentao and Xiong, Yixiao and Fan, Yunhui and Wu, Yang and Zhao, Jianping and Shang, Changzhen and Liang, Huifang and Zhang, Wanguang},
  title = {Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {46},
  doi = {10.1002/advs.202401399}
}
Kostenlos starten →